Pexa-Vec

BIOLOGICAL2 trials

Sponsors

Centre Leon Berard, National Cancer Institute (NCI)

Conditions

Advanced TumorColorectal AdenocarcinomaColorectal CancerColorectal CarcinomaColorectal NeoplasmsMetastatic TumorRefractory Cancer

Phase 1

Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.

CompletedNCT02977156

Centre Leon BerardAdvanced Tumor, Metastatic Tumor

Start: 2017-01-03End: 2022-06-06Updated: 2022-07-25

A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

CompletedNCT03206073

National Cancer Institute (NCI)Colorectal Adenocarcinoma, Colorectal Cancer, Colorectal Carcinoma +2

Start: 2017-12-07End: 2022-06-30Updated: 2023-10-24

Related Papers

Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer

Journal for ImmunoTherapy of Cancer2023-02-0161 citations

A phase I/II study of Pexa-Vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer.

Journal of Clinical Oncology2020-02-0119 citations

A phase I/II study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer: Safety report.

Journal of Clinical Oncology2019-01-2911 citations